Isoprostanes and other markers of peroxidation in atherosclerosis

Author： Patrignani Paola Tacconelli Stefania

ISSN： 1366-5804

Source： Biomarkers, Vol.10, Iss.1, 2005-11, pp. : 24-29

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Several lines of evidence suggest that reactive oxygen species play a role in the development of vasculopathies, including those that define atherosclerosis, hypertension and restenosis after angioplasty. Confused picture emerging from prospective clinical trials of anti-oxidants may reflect inadequacy of traditional indices of lipid peroxidation in the recruitment of appropriate patients and in guiding the selection of the appropriate dose of anti-oxidant to be tested. Ex vivo indices of oxidant stress could have questionable veracity in assessing the actual rate of lipid peroxidation in vivo . The measurement of F 2 -isoprostanes (F 2 -iPs), formed non-enzimatically through free radical catalysed attack on esterified arachidonate, provides a reliable tool for identifyng populations with enhanced rates of lipid peroxidation. Enhanced formation of F 2 -iPs, together with increased in vivo platelet activation, has been reported in association with several cardiovascular risk factors. Thus, it has been suggested that F 2 -iPs may transduce oxidant stress-dependent platelet activation. Measurements of 8-iso-PGF 2  , an abundant F 2 -iP formed in vivo , in urine may provide sensitive biochemical end-points for the assessment of the oxidant status of the patient and the true efficacy of anti-oxidant therapies. The incorporation of such biochemical end-points in clinical trials may help to verify the reliability of the oxidative modification hypothesis in the development of atheroscelerosis.